UroGen Pharma Ltd.
URGN
$9.66
-$0.01-0.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.54% | 15.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.54% | 15.36% | |||
| Cost of Revenue | 0.73% | 10.05% | |||
| Gross Profit | -2.89% | 15.96% | |||
| SG&A Expenses | 16.64% | -3.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.59% | -10.36% | |||
| Operating Income | -51.37% | 32.10% | |||
| Income Before Tax | -47.84% | 29.32% | |||
| Income Tax Expenses | 2,810.99% | 139.47% | |||
| Earnings from Continuing Operations | -58.46% | 29.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -58.46% | 29.13% | |||
| EBIT | -51.37% | 32.10% | |||
| EBITDA | -51.57% | 32.18% | |||
| EPS Basic | -45.20% | 39.44% | |||
| Normalized Basic EPS | -31.20% | 39.61% | |||
| EPS Diluted | -45.20% | 39.44% | |||
| Normalized Diluted EPS | -31.20% | 39.61% | |||
| Average Basic Shares Outstanding | 9.12% | 17.05% | |||
| Average Diluted Shares Outstanding | 9.12% | 17.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||